Since we previously found that mesalazine exerts antifibrotic effects in vitro and in vivo by modulating ERK1/2‐SMAD2/3‐, NFκB‐ and osteopontin‐signaling (Hoffmann et al., 2021; Künzel et al., 2021; Newe et al., 2021), we tested the effects of systemically administered mesalazine on cardiac function and fibrotic remodeling following MI. Here, SPP1 is linked to myocardial infarction.